Groupama Asset Managment Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment lifted its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 5.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,069,211 shares of the company's stock after acquiring an additional 52,020 shares during the quarter. Groupama Asset Managment owned 0.67% of Ionis Pharmaceuticals worth $32,258,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in IONS. Raymond James Financial Inc. purchased a new stake in Ionis Pharmaceuticals during the fourth quarter worth about $3,692,000. Mariner LLC lifted its holdings in shares of Ionis Pharmaceuticals by 19.6% in the fourth quarter. Mariner LLC now owns 27,661 shares of the company's stock valued at $967,000 after purchasing an additional 4,534 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Ionis Pharmaceuticals by 77.7% in the fourth quarter. Canada Pension Plan Investment Board now owns 19,900 shares of the company's stock valued at $696,000 after purchasing an additional 8,700 shares in the last quarter. Natixis purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $581,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Ionis Pharmaceuticals by 229.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 14,157 shares of the company's stock valued at $495,000 after purchasing an additional 9,856 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on IONS. Guggenheim reduced their price target on shares of Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Wells Fargo & Company upped their price target on shares of Ionis Pharmaceuticals from $77.00 to $82.00 and gave the stock an "overweight" rating in a research report on Friday. HC Wainwright upped their price target on shares of Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday. Citigroup upped their price target on shares of Ionis Pharmaceuticals from $65.00 to $69.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Raymond James Financial upped their price target on shares of Ionis Pharmaceuticals from $60.00 to $64.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $60.85.

Ionis Pharmaceuticals Trading Down 1.3%

Shares of Ionis Pharmaceuticals stock traded down $0.55 during trading hours on Friday, hitting $42.69. The company's stock had a trading volume of 1,859,935 shares, compared to its average volume of 2,166,917. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $50.43. The business has a fifty day moving average of $41.38 and a 200 day moving average of $35.11. The company has a market capitalization of $6.80 billion, a PE ratio of -23.20 and a beta of 0.25. The company has a quick ratio of 2.86, a current ratio of 2.87 and a debt-to-equity ratio of 0.99.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.51. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. The company had revenue of $452.00 million during the quarter, compared to analyst estimates of $270.90 million. During the same quarter in the prior year, the business earned ($0.45) earnings per share. The business's quarterly revenue was up 100.9% compared to the same quarter last year. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Insider Buying and Selling

In other news, EVP C Frank Bennett sold 10,000 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $43.98, for a total value of $439,800.00. Following the completion of the sale, the executive vice president owned 93,466 shares of the company's stock, valued at $4,110,634.68. This represents a 9.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard S. Geary sold 10,000 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $42.86, for a total transaction of $428,600.00. Following the completion of the transaction, the executive vice president owned 89,492 shares of the company's stock, valued at $3,835,627.12. This trade represents a 10.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,141 shares of company stock valued at $1,644,606. 2.60% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.